Document Detail


Racial disparities in tissue plasminogen activator treatment rate for stroke: a population-based study.
MedLine Citation:
PMID:  21719765     Owner:  NLM     Status:  MEDLINE    
Abstract/OtherAbstract:
BACKGROUND AND PURPOSE: Some prior studies have shown that racial disparities exist in intravenous tissue plasminogen activator (tPA) use for acute ischemic stroke. We sought to determine whether race was associated with tPA treatment for stroke in a predominantly black urban population.
METHODS: Systematic chart abstraction was performed on consecutive hospitalized patients with ischemic stroke from all 7 acute care hospitals in the District of Columbia from February 1, 2008, to January 31, 2009.
RESULTS: Of 1044 patients with ischemic stroke, 74% were black, 19% non-Hispanic white, and 5% received intravenous tPA. Blacks were one third less likely than whites to receive intravenous tPA (3% versus 10%, P<0.001). However, blacks were also less likely than whites to present within 3 hours of symptom onset (13% versus 21%, P=0.004) and also less likely to be tPA-eligible (5% versus 13%, P<0.001). Of those who presented within 3 hours, blacks were almost half as likely to be treated with intravenous tPA than whites (27% versus 46%, P=0.023). The treatment rate for tPA-eligible patients was similar for blacks and whites (70% versus 76%, P=0.62).
CONCLUSIONS: In this predominantly black urban population hospitalized for acute ischemic stroke, blacks were significantly less likely to be treated with intravenous tPA due to contraindications to treatment, delayed presentation, and stroke severity. Effective interventions designed to increase treatment in this population need to focus on culturally relevant education programs designed to address barriers specific to this population.
Authors:
Amie W Hsia; Dorothy F Edwards; Lewis B Morgenstern; Jeffrey J Wing; Nina C Brown; Regina Coles; Sarah Loftin; Andrea Wein; Sara S Koslosky; Sabiha Fatima; Brisa N Sánchez; Ali Fokar; M Chris Gibbons; Nawar Shara; Annapurni Jayam-Trouth; Chelsea S Kidwell
Related Documents :
14673725 - Prevention of gallstones by ursodeoxycholic acid after cardiac surgery.
6361755 - Do thiazides prevent recurrent idiopathic renal calcium oxalate stones?
9187895 - Endopyelotomy with the acucise cutting balloon device. early clinical experience.
10146425 - Improved results of extracorporeal shock wave lithotripsy with the dornier mpl 9000 for...
15175935 - Endovascular abdominal aortic aneurysm repair in the octogenarian.
21225515 - Thalamic deep brain stimulation for tremor among multiple sclerosis patients.
Publication Detail:
Type:  Journal Article; Research Support, N.I.H., Extramural     Date:  2011-06-30
Journal Detail:
Title:  Stroke; a journal of cerebral circulation     Volume:  42     ISSN:  1524-4628     ISO Abbreviation:  Stroke     Publication Date:  2011 Aug 
Date Detail:
Created Date:  2011-07-26     Completed Date:  2012-08-10     Revised Date:  2013-06-28    
Medline Journal Info:
Nlm Unique ID:  0235266     Medline TA:  Stroke     Country:  United States    
Other Details:
Languages:  eng     Pagination:  2217-21     Citation Subset:  IM    
Affiliation:
Washington Hospital Center, Washington, DC 20010, USA. hsiaa@ninds.nih.gov
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Descriptor/Qualifier:
African Americans
Aged
Aged, 80 and over
Brain Ischemia / drug therapy*
European Continental Ancestry Group
Female
Fibrinolytic Agents / therapeutic use*
Healthcare Disparities*
Humans
Male
Middle Aged
Stroke / drug therapy*
Thrombolytic Therapy
Time Factors
Tissue Plasminogen Activator / therapeutic use*
Grant Support
ID/Acronym/Agency:
U54 NS057405-01A1/NS/NINDS NIH HHS; U54NS057405/NS/NINDS NIH HHS
Chemical
Reg. No./Substance:
0/Fibrinolytic Agents; EC 3.4.21.68/Tissue Plasminogen Activator
Comments/Corrections

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine


Previous Document:  Early Ischemic Change on CT Versus Diffusion-Weighted Imaging for Patients With Stroke Receiving Int...
Next Document:  Cost-effectiveness of tissue-type plasminogen activator in the 3- to 4.5-hour time window for acute ...